Video Experimental Relacionado
Updated: Jan 13, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.8K
Menopausia, terapia hormonal y riesgo cardiovascular
Geneviève Plu-Bureau1, Iphigénie Cavadias1, Brigitte Raccah-Tebeka2
1Unité de gynécologie endocrinienne, hôpital Port-Royal, Université Paris Cité, Paris, Inserm UMR 1153, Obstetrical, Perinatal, Paediatric Life course Epidemiology (OPPaLE), centre d'épidémiologie et de statistiques Sorbonne Paris Cité (CRESS), Paris, France.
Medecine sciences : M/S
|January 6, 2026
Resumen
La menopausia es el momento ideal para evaluar a las mujeres en busca de factores de riesgo de enfermedad cardiovascular. El estradiol transdérmico y la progesterona natural ofrecen la terapia hormonal más segura para las mujeres elegibles, que requiere una evaluación de riesgo anual.
Área de la Ciencia:
- Cardiología
- Salud de la Mujer
- Endocrinología
Sus antecedentes:
- Las enfermedades cardiovasculares (ECV) son una de las principales causas de muerte en mujeres francesas.
- La menopausia presenta una ventana crítica para la evaluación del riesgo cardiovascular.
- El síndrome climatérico incapacitante a menudo requiere consideraciones de tratamiento.
Objetivo del estudio:
- Destacar la importancia de la detección del riesgo cardiovascular durante la menopausia.
- Evaluar la seguridad y eficacia de la terapia hormonal menopáusica (THM).
- Recomendar la THM óptima para mujeres con síndrome climatérico.
Principales métodos:
- Revisión de las guías clínicas actuales y la literatura sobre factores de riesgo de ECV en mujeres menopáusicas.
- Análisis del perfil de seguridad de diferentes formulaciones de THM.
- Énfasis en la necesidad de seguimiento anual para el manejo de la THM.
Principales resultados:
- La menopausia se identifica como el período óptimo para la detección integral de los factores de riesgo cardiovascular.
- El estradiol transdérmico combinado con progesterona natural se presenta como la opción de THM más segura para mujeres sin antecedentes de histerectomía.
- La evaluación anual de la tolerabilidad del tratamiento y los factores de riesgo cardiovascular es crucial.
Conclusiones:
- La detección sistemática del riesgo cardiovascular durante la menopausia es esencial.
- Formulaciones específicas de THM (estradiol transdérmico/progesterona natural) ofrecen un perfil de beneficio/riesgo favorable para mujeres seleccionadas.
- El monitoreo continuo es vital para optimizar la seguridad y efectividad de la THM.
Videos de Conceptos Relacionados
01:28Menopause
3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
01:22Hormonal Regulation of the Menstrual Cycle
1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
01:17Hormonal Regulation of Blood Pressure
5.8K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
5.8K
01:27Psychoneuroimmunology: Cardiovascular Disease
382
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
382
01:19Mitral Valve Prolapse III: Nursing Management
279
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
279
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915